Matt Zuga, CFO & Chief Business Officer at Acumen Pharmaceuticals, Inc. (ABOS), sold 4,160 shares at $1.81 ($8K) on 2026-01-21, disclosed to the SEC on 2026-01-23.
Scheduled sale ($8k) by CFO & Chief Business Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.81 | 2,473 | $4K | 58.8% |
| 2 | $1.86 | 1,687 | $3K | 41.2% |
| Total | $1.83 avg | 4,160 | $8K | 100% |
| Filing → |
| ABOS | SELL | 2025-01-23 | $57K | — | Filing → |
| ABOS | SELL | 2025-01-07 | $24K | — | Filing → |
| ABOS | SELL | 2024-01-19 | $16K | — | Filing → |